{"id":742976,"date":"2023-03-28T06:55:01","date_gmt":"2023-03-28T10:55:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/"},"modified":"2023-03-28T06:55:01","modified_gmt":"2023-03-28T10:55:01","slug":"synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/","title":{"rendered":"Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., March  28, 2023  (GLOBE NEWSWIRE) &#8212; Synlogic, Inc.\u00a0(Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company\u2019s application for orphan designation for SYNB1934 for the treatment of phenylketonuria (PKU).<\/p>\n<p>\u201cWe are pleased that the EMA has issued a positive opinion for orphan designation for SYNB1934, in recognition of the urgent need for new treatment options for people living with this devastating disease,\u201d said Aoife Brennan, M.B. Ch.B.,\u00a0Synlogic President and Chief Executive Officer. \u201cThis designation also comes at a pivotal time as we prepare to begin our Phase 3 trial for PKU in the first half of this year.\u201d<\/p>\n<p>SYNB1934 has also been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration (FDA).<\/p>\n<p>\n        <strong>About the European Medicines Agency Orphan Designation<\/strong>\n      <\/p>\n<p>The EMA\u2019s orphan designation\u00a0is available to companies developing treatments\u00a0for life-threatening or chronically debilitating conditions\u00a0that affect fewer\u00a0than five in 10,000 persons in the\u00a0European Union (EU).\u00a0Medicines that meet the EMA\u2019s orphan designation criteria qualify for financial and regulatory incentives that include a 10-year period of marketing exclusivity in the EU after product approval, protocol assistance from the EMA at reduced fees during the product development phase and access to centralized marketing authorization.<\/p>\n<p>\n        <strong>About SYNB1934<\/strong>\n      <\/p>\n<p>SYNB1934 is an orally administered, non-systemically absorbed drug candidate being studied as potential biotherapeutic for phenylketonuria (PKU). PKU is an inherited rare metabolic disease caused by an inborn error of metabolism that impairs the breakdown of phenylalanine (Phe), an amino acid found in all protein-containing foods. Treatment options for PKU are currently limited, with a majority of individuals with PKU in need of treatment or not adequately responding to treatment. Synlogic designed SYNB1934 to reduce levels of Phe in people with PKU by consuming Phe in the gastrointestinal (GI) tract, using genetic engineering of the well-characterized probiotic <em>E. coli<\/em> Nissle. Findings to date support the potential for an oral, efficacious, safe, convenient, and flexible treatment option for PKU. SYNB1934 has also been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration (FDA).<\/p>\n<p>\n        <strong>About\u00a0Synlogic\u00a0<\/strong>\n      <\/p>\n<p>Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic\u2019s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic\u2019s reproducible, target-specific drug design.\u00a0Synlogic\u00a0uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases. In addition to its clinical programs,\u00a0Synlogic\u00a0has a research collaboration with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD). Synlogic has also developed two drug candidates through a research collaboration with Ginkgo Bioworks: SYNB1353, designed to consume methionine for the potential treatment of HCU, and SYNB2081, designed to lower uric acid for the potential treatment of gout. For additional information visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=90MSg8aeN99wTiD0e-gtGT321LISZf4Ho-rJsBCIqYKvkAV-xe9aFZMNTTS6PrBKdFbZdQE71L63RmZREUGs_QIfeGpl8W6GBOOoRh7Ps9gzH3su5QBPZX0yIipc0zxVVWBIllqBcYGPDYlJoxEzkQhD9_0ulcwDx1ExsFUsCDprEYaAYQMzTCq5-YG-zoBw0PhJA0LJOebEOY8GL5q-7ttL0XPaErYKHz_3k9VWGvXDqOmtXW4VadSqE0-Y-h05\" rel=\"nofollow noopener\" target=\"_blank\">www.synlogictx.com<\/a>.\u00a0<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains &#8220;forward-looking statements&#8221; that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;look forward, &#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;on track, &#8221; &#8220;plan,&#8221; &#8220;predict&#8221; and similar expressions and their variants, as they relate to\u00a0Synlogic, may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of\u00a0Synlogic&#8217;s\u00a0approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approach\u00a0Synlogic\u00a0is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of\u00a0Synlogic&#8217;s\u00a0clinical trials of SYNB1934, SYNB1353, SYNB8802 and SYNB2081 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of\u00a0Synlogic\u00a0to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading &#8220;Risk Factors&#8221; in\u00a0Synlogic&#8217;s\u00a0filings with the\u00a0U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect\u00a0Synlogic&#8217;s\u00a0current views with respect to future events.\u00a0Synlogic\u00a0anticipates that subsequent events and developments will cause its views to change. However, while\u00a0Synlogic\u00a0may elect to update these forward-looking statements in the future,\u00a0Synlogic\u00a0specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing\u00a0Synlogic&#8217;s\u00a0view as of any date subsequent to the date hereof.<\/p>\n<p>\n        <strong>Media Contact: <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=D1FWBS-bG7-dT3uMMj8zqSUjejZqdnpGNjS2Etf1yYIsGs9GTzeNfi9Tec9O_RJkCgRfucT4zIOrAOOyzyTWEOzdEJL74i8h-Ht9Op7rG3I=\" rel=\"nofollow noopener\" target=\"_blank\">media@synlogictx.com<\/a>\n      <\/p>\n<p>\n        <strong>Investor Relations:<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YzmWDlqy877Ua686J6cIXSEpjFwQt15g_k2wwYG1OgNKjAyk0ErXwUPdSMQvulH3z3AlVp7_IIZwo44lYEiKlViZLgw6t9mQyxacvmuFufQ=\" rel=\"nofollow noopener\" target=\"_blank\">investor@synlogictx.com<\/a>\n      <\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjI0NyM1NDkzOTE3IzIwODY5ODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjcwYmU5OGYtODAzOC00ZTg4LWFmNTAtMzA0MDM3ZjJhMmE1LTEwOTg1NTE=\/tiny\/Synlogic-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Synlogic, Inc.\u00a0(Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company\u2019s application for orphan designation for SYNB1934 for the treatment of phenylketonuria (PKU). \u201cWe are pleased that the EMA has issued a positive opinion for orphan designation for SYNB1934, in recognition of the urgent need for new treatment options for people living with this devastating disease,\u201d said Aoife Brennan, M.B. Ch.B.,\u00a0Synlogic President and Chief Executive Officer. \u201cThis designation also comes at a pivotal time as we prepare to begin our Phase 3 trial for PKU in the first half of this year.\u201d SYNB1934 has also been &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-742976","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Synlogic, Inc.\u00a0(Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company\u2019s application for orphan designation for SYNB1934 for the treatment of phenylketonuria (PKU). \u201cWe are pleased that the EMA has issued a positive opinion for orphan designation for SYNB1934, in recognition of the urgent need for new treatment options for people living with this devastating disease,\u201d said Aoife Brennan, M.B. Ch.B.,\u00a0Synlogic President and Chief Executive Officer. \u201cThis designation also comes at a pivotal time as we prepare to begin our Phase 3 trial for PKU in the first half of this year.\u201d SYNB1934 has also been &hellip; Continue reading &quot;Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T10:55:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjI0NyM1NDkzOTE3IzIwODY5ODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria\",\"datePublished\":\"2023-03-28T10:55:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\\\/\"},\"wordCount\":902,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjI0NyM1NDkzOTE3IzIwODY5ODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\\\/\",\"name\":\"Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjI0NyM1NDkzOTE3IzIwODY5ODA=\",\"datePublished\":\"2023-03-28T10:55:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjI0NyM1NDkzOTE3IzIwODY5ODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjI0NyM1NDkzOTE3IzIwODY5ODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/","og_locale":"en_US","og_type":"article","og_title":"Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria - Market Newsdesk","og_description":"CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Synlogic, Inc.\u00a0(Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company\u2019s application for orphan designation for SYNB1934 for the treatment of phenylketonuria (PKU). \u201cWe are pleased that the EMA has issued a positive opinion for orphan designation for SYNB1934, in recognition of the urgent need for new treatment options for people living with this devastating disease,\u201d said Aoife Brennan, M.B. Ch.B.,\u00a0Synlogic President and Chief Executive Officer. \u201cThis designation also comes at a pivotal time as we prepare to begin our Phase 3 trial for PKU in the first half of this year.\u201d SYNB1934 has also been &hellip; Continue reading \"Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-28T10:55:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjI0NyM1NDkzOTE3IzIwODY5ODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria","datePublished":"2023-03-28T10:55:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/"},"wordCount":902,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjI0NyM1NDkzOTE3IzIwODY5ODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/","name":"Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjI0NyM1NDkzOTE3IzIwODY5ODA=","datePublished":"2023-03-28T10:55:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjI0NyM1NDkzOTE3IzIwODY5ODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjI0NyM1NDkzOTE3IzIwODY5ODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-receives-positive-opinion-on-orphan-designation-from-the-european-medicines-agency-for-synb1934-for-the-treatment-of-phenylketonuria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=742976"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742976\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=742976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=742976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=742976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}